{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:28:10Z","timestamp":1792020490317,"version":"4.4.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Zolpidem is indicated in cases of severe insomnia in adults and, as for BDZs, its assumption should be limited to short periods under close medical supervision. Since several drugs cause corrected QT interval (QTc) elongation, the authors investigated whether high daily doses of Zolpidem could cause QTc elongation. The study was conducted in the Addiction Medicine Unit of the G.B. Rossi University Hospital in Verona. The data were collected from hospitalizations carried out between January 2015 and February 2020 and refer to a total of 74 patients, 38 males and 36 females, who were treated for detoxification from high doses of Zolpidem with the \u201cVerona Detox Approach With Flumazenil.\u201d One patient out of 74 had QTc elongation (479 ms). The patient was male and took a daily dose of 50 mg of Zolpidem; he did not take concomitant therapies that could cause QTc lengthening. He had no electrolyte alterations, no contemporary or previous intake of barbiturates, heroin, cocaine, THC, alcohol, NMDA or nicotine which could cause an elongation of the QTc interval. The present study highlights the low risk of QTc elongation due to high dosages of Zolpidem; however, if, on one hand, we can affirm that Zolpidem is a safe drug, on the other, the widespread use of high dosages of this drug for prolonged periods of time is problematic and worrying.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.1033061","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:09:12Z","timestamp":1666267752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: High doses of Zolpidem and QT interval lengthening: Is there a relationship? A case series"],"prefix":"10.3389","volume":"13","author":[{"given":"Simone","family":"Campagnari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fusina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Lugoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"w13745","DOI":"10.4414\/smw.2013.13745","article-title":"Perceptions of German GPs on benefits and risks of benzodiazepines and Z-drugs.","volume":"143","author":"Hoffmann","year":"2013","journal-title":"Swiss Med Weekly."},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/imj.12315","article-title":"Twenty-year trends in benzodiazepine dispensing in the Australian population.","volume":"44","author":"Islam","year":"2014","journal-title":"Intern Med J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.1367","article-title":"Trends in psychotropic medication use among U.S. adults.","volume":"16","author":"Paulose-Ram","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B4","first-page":"964","article-title":"GPs\u2019 attitudes to benzodiazepine and \u201cZ-drug\u201d prescribing: a barrier to implementation of evidence and guidance on hypnotics.","volume":"56","author":"Siriwardena","year":"2006","journal-title":"Br J Gen Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003088-200443040-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.","volume":"43","author":"Drover","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsmc.2014.11.002","article-title":"Non-Benzodiazepine receptor agonists for Insomnia.","volume":"10","author":"Becker","year":"2015","journal-title":"Sleep Med Clin."},{"key":"B7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13181-013-0294-y","article-title":"In the Zzz zone: the effects of Z-drugs on human performance and driving.","volume":"9","author":"Gunja","year":"2013","journal-title":"J Med Toxicol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/13803395.2014.928268","article-title":"The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis.","volume":"36","author":"Stranks","year":"2014","journal-title":"J Clin Exp Neuropsychol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2165\/11312920-000000000-00000","article-title":"Comparative tolerability of newer agents for Insomnia.","volume":"32","author":"Zammit","year":"2009","journal-title":"Drug Safety."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1046\/j.1360-0443.2003.00491.x","article-title":"Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data.","volume":"98","author":"Hajak","year":"2003","journal-title":"Addiction."},{"key":"B11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/0269881103017001723","article-title":"Zolpidem dependence case series: possible neurobiological mechanisms and clinical management.","volume":"17","author":"Liappas","year":"2003","journal-title":"J Psychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S2215-0366(19)30331-1","article-title":"Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England.","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0091-3057(98)00102-6","article-title":"Behavioral pharmacology of zolpidem relative to benzodiazepines: a review.","volume":"61","author":"Rush","year":"1998","journal-title":"Pharmacol Biochem Behav."},{"key":"B14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ijnp\/pyz007","article-title":"An insight into Z-Drug abuse and dependence: an examination of reports to the european medicines agency database of suspected adverse drug reactions.","volume":"22","author":"Schifano","year":"2019","journal-title":"Int J Neuropsychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/ipj.ipj_80_14","article-title":"High-dose zolpidem dependence - Psychostimulant effects? A case report and literature review.","volume":"25","author":"Chattopadhyay","year":"2016","journal-title":"Ind Psychiatry J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"109643","DOI":"10.1016\/j.pnpbp.2019.109643","article-title":"Zolpidem stimulant effect: induced mania case report and systematic review of cases.","volume":"94","author":"Sabe","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1365-2125.2007.02861.x","article-title":"Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey.","volume":"64","author":"Victorri-Vigneau","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00702-020-02285-w","article-title":"Adult attention-deficit\/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug.","volume":"128","author":"Federico","year":"2021","journal-title":"J Neural Trans."},{"key":"B19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000507852","article-title":"Adult attention-deficit\/hyperactivity disorder and quality of life in high-dose benzodiazepine and related Z-Drug users.","volume":"26","author":"Lugoboni","year":"2020","journal-title":"Eur Addict Res."},{"key":"B20","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms.","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart."},{"key":"B21","author":"Jordan","year":"2019","journal-title":"ECG: Basic Principles of ECG Analysis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1067\/mhj.2002.120295","article-title":"Long QT syndrome: diagnosis and management.","volume":"143","author":"Khan","year":"2002","journal-title":"Am Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s0025-7125(05)70318-7","article-title":"Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes.","volume":"85","author":"Passman","year":"2001","journal-title":"Med Clin North Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/sj.bjp.0700989","article-title":"The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes.","volume":"120","author":"Suessbrich","year":"1997","journal-title":"Br J Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/01.cir.93.3.407","article-title":"Extracellular potassium modulation of drug block of IKr. implications for torsade de pointes and reverse use-dependence.","volume":"93","author":"Yang","year":"1996","journal-title":"Circulation."},{"key":"B26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1001\/jama.270.21.2590","article-title":"Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.","volume":"270","author":"Makkar","year":"1993","journal-title":"JAMA."},{"key":"B28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/01.md.0000085057.63483.9b","article-title":"Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.","volume":"82","author":"Zeltser","year":"2003","journal-title":"Medicine."},{"key":"B29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","article-title":"QTc prolongation and antipsychotic medications in a sample of 1017 patients with Schizophrenia.","volume":"34","author":"Ozeki","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"857376","DOI":"10.3389\/fpsyt.2022.857376","article-title":"Addiction of high dose of benzodiazepine: verona detox approach with flumazenil.","volume":"13","author":"Casari","year":"2022","journal-title":"Front Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3389\/fnins.2020.00747","article-title":"Detoxification improves multidomain cognitive dysfunction in high-dose benzodiazepine abusers.","volume":"14","author":"Federico","year":"2020","journal-title":"Front Neurosci."},{"key":"B32","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/papr.12776","article-title":"Perioperative pharmacological sleep-promotion and pain control: a systematic review.","volume":"19","author":"Bjurstr\u00f6m","year":"2019","journal-title":"Pain Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"18m12149","DOI":"10.4088\/JCP.18m12149","article-title":"Predictors of long-term and high-dose use of zolpidem in veterans.","volume":"80","author":"Kim","year":"2019","journal-title":"J Clin Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3350\/cmh.2018.0084","article-title":"Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: a randomized, placebo-controlled trial.","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Mol Hepatol."},{"key":"B36","first-page":"799","article-title":"Benzodiazepine use and motor vehicle accidents. Systematic review of reported association.","volume":"44","author":"Thomas","year":"1998","journal-title":"Can Fam Phys."},{"key":"B37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugalcdep.2014.06.020","article-title":"Quality of life in a cohort of high-dose benzodiazepine dependent patients.","volume":"142","author":"Lugoboni","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.5665\/SLEEP.1272","article-title":"Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.","volume":"34","author":"Mets","year":"2011","journal-title":"Sleep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/aas.12257","article-title":"Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit.","volume":"58","author":"Beitland","year":"2014","journal-title":"Acta Anaesthesiol Scand."},{"key":"B40","doi-asserted-by":"crossref","first-page":"212178","DOI":"10.1100\/2012\/212178","article-title":"Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review.","volume":"2012","author":"Kallergis","year":"2012","journal-title":"ScientificWorldJournal."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1124\/jpet.105.093393","article-title":"Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.","volume":"316","author":"Katchman","year":"2006","journal-title":"J Pharmacol Exp Therap."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa040582","article-title":"Oral erythromycin and the risk of sudden death from cardiac causes.","volume":"351","author":"Ray","year":"2004","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1033061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:09:17Z","timestamp":1666267757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1033061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":42,"alternative-id":["10.3389\/fpsyt.2022.1033061"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1033061","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"1033061"}}